One of the foremost diabetes researchers in Canada has been joined by the US Group Public Citizen in calling for the FDA (Food and Drug Administration) to curtail a major international diabetes drug trial .
The TIDE trial is investigating the risks of diabetes drug Avandia, and the expert calls for it to be stopped because there is not enough evidence to show the drug is more dangerous than a similar drug, Actos . Both drugs, however, are more dangerous that older diabetes drugs .
Dr. David Juurlink, researcher at Sunnybrook Health Sciences Centre in Toronto, reportedly commented: “It really does not make sense that this trial should continue. Given the gathering cloud of data regarding the risk of rosiglitazone as compared to pioglitazone, what really is the `big picture’ purpose of this trial? To see if the previous studies are right, and that rosiglitazone — which has no advantage over pioglitazone — really is more dangerous than pioglitazone? The need for certainty is not a reason to do a trial . These are patients, not guinea pigs.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…